{"id":"ro0503821-1x-4-weeks","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the S1P1 receptor, RO0503821 modulates sphingosine-1-phosphate signaling, which plays a crucial role in lymphocyte trafficking and immune responses.","oneSentence":"RO0503821 is a small molecule that targets the S1P1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:37.614Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT00048048","phase":"PHASE2","title":"A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-03","conditions":"Anemia","enrollment":65},{"nctId":"NCT00077610","phase":"PHASE3","title":"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-02","conditions":"Anemia","enrollment":673},{"nctId":"NCT00364832","phase":"PHASE2","title":"A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2001-10","conditions":"Anemia","enrollment":137},{"nctId":"NCT00048035","phase":"PHASE2","title":"A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-03","conditions":"Anemia","enrollment":91},{"nctId":"NCT00576303","phase":"PHASE3","title":"A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-04","conditions":"Anemia","enrollment":200},{"nctId":"NCT00077623","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-03","conditions":"Anemia","enrollment":572}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mircera"],"phase":"phase_3","status":"active","brandName":"RO0503821 (1x/4 Weeks)","genericName":"RO0503821 (1x/4 Weeks)","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RO0503821 is a small molecule that targets the S1P1 receptor. Used for Relapsing forms of multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}